Skip to main content
Year archive

BioInvent International — 2023 filings

All 29 regulatory filings released by BioInvent International (BINV) in 2023, sourced directly from the official regulator.

29 Filings
2023 Period
2023 filings (29)
Filing Released Lang
BioInvent presents positive first clinical data on anti-FcyRIIB antibody BI-1607
Regulatory Filings
2023-12-05 English
BioInvent presenterar positiva kliniska data för anti-FcyRIIB-antikroppen BI-1607
Earnings Release FY 2023
2023-12-05 Swedish
BioInvent presents positive data at SITC from clinical Phase 1/2a trial of BI-1808 as single agent
Regulatory Filings
2023-11-03 English
BioInvent presenterar positiva data på SITC från klinisk fas 1/2a-studie med BI-1808 som monoterapi
Regulatory Filings
2023-11-03 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report 9M 2023
2023-10-26 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report 9M 2023
2023-10-26 English
Interim / Quarterly Report 2023
Interim / Quarterly Report Q2 2023
2023-08-30 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Q2 2023
2023-08-30 English
BioInvent rapporterar starka interims-säkerhetsdata och tidiga signaler på effekt i fas 1/2a-studien med anti-TNFR2-antikroppen BI-1808 i långt framskriden cancer
Report Publication Announcement
2023-06-21 Swedish
BioInvent reports strong interim safety data and early signs of efficacy in Phase 1/2a trial with anti-TNFR2 antibody BI-1808 in advanced malignancies
Regulatory Filings
2023-06-21 English
BioInvent announces additional efficacy data from intravenous part of Phase 1/2 trial with BI-1206 in solid tumors
Regulatory Filings
2023-06-07 English
BioInvent meddelar ytterligare effektdata från den intravenösa delen av fas 1/2-studien med BI-1206 i solida tumörer
Regulatory Filings
2023-06-07 Swedish
BioInvent and Transgene report positive Phase 1a data on oncolytic virus BT-001 in solid tumors
Regulatory Filings
2023-05-25 English
BioInvent och Transgene rapporterar positiva fas 1a-data för det onkolytiska viruset BT-001 i solida tumörer
Report Publication Announcement
2023-05-25 Swedish
Resolutions at BioInvent’s Annual General Meeting 2023
AGM Information
2023-04-27 English
Beslut på BioInvents årsstämma 2023
AGM Information
2023-04-27 Swedish
Earnings Release 2023
Earnings Release Q1 2023
2023-04-26 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Q1 2023
2023-04-26 English
BioInvent announces a fourth complete response in Phase 1/2 trial with BI-1206 in non-Hodgkin’s lymphoma
Earnings Release FY 2023
2023-04-20 English
En fjärde fullständig respons i BioInvents fas 1/2-studie med BI-1206 i non-Hodgkins lymfom
Regulatory Filings
2023-04-20 Swedish
Annual Report (ESEF) 2022
Annual Report (ESEF) FY 2022
2023-04-06 Swedish
Notice to Annual General Meeting in BioInvent International AB
AGM Information
2023-03-27 English
Kallelse till årsstämma i BioInvent International AB
AGM Information
2023-03-27 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Q4 2022
2023-02-22 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report FY 2022
2023-02-22 English
Change in the number of shares and votes in BioInvent International AB
Declaration of Voting Results & Voting Rights Announcements
2023-01-31 English
Ändring av antalet aktier och röster i BioInvent International AB
Declaration of Voting Results & Voting Rights Announcements
2023-01-31 Swedish
BioInvent selected to The Leukemia & Lymphoma Society’s Therapy Acceleration Program and receives $3 million strategic equity investment
Capital/Financing Update
2023-01-17 English
BioInvent utvalt till The Leukemia & Lymphoma Society's Therapy Acceleration Program och erhåller strategisk investering om 3 miljoner USD
Capital/Financing Update
2023-01-17 Swedish